MEDLINE INDUSTRIES, L.P. (FORMERLY MEDLINE INDUSTRIES, INC.)

Lobbying Spend

—

Filings

Firms Hired

Active Period

2018–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	3	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
MAYER BROWN LLP	—	34

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	26
SENATE	26
Health & Human Services, Dept of (HHS)	8
Food & Drug Administration (FDA)	7
White House Office	5
Natl Economic Council (NEC)	4
Vice President of the U.S.	4
U.S. Trade Representative (USTR)	3

Most frequently reported lobbying issues

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 4521117th Congress

United States Innovation and Competition Act of 2021

2022 · second_quarter · Firm: MAYER BROWN LLP

Cited source text and reported amounts

Issues related to the US Innovation and Competition Act (USICA - S. 1260) and the America COMPETES Act of 2022 (H.R. 4521).

Client expense: — · Firm income: $40,000

Matched citations: H.R. 4521

S. 1260117th Congress

United States Innovation and Competition Act of 2021

2022 · second_quarter · Firm: MAYER BROWN LLP

Cited source text and reported amounts

Issues related to the US Innovation and Competition Act (USICA - S. 1260) and the America COMPETES Act of 2022 (H.R. 4521).

Client expense: — · Firm income: $40,000

Matched citations: S. 1260

MEDLINE INDUSTRIES, L.P. (FORMERLY MEDLINE INDUSTRIES, INC.) — Lobbying Disclosure | Poliscope